share_log

BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5

Benzinga Real-time News ·  Jun 1, 2022 07:30

BTIG analyst Kaveri Pohlman initiates coverage on NexImmune (NASDAQ:NEXI) with a Buy rating and announces Price Target of $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment